Cargando…

Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy

Systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) are two autoimmune diseases characterised by the production of pathogenic autoreactive antibodies. Their aetiology is poorly understood. Nevertheless, they have been shown to involve several factors, such as infections and epige...

Descripción completa

Detalles Bibliográficos
Autores principales: Morel, Marie, Pochard, Pierre, Echchih, Wiam, Dueymes, Maryvonne, Bagacean, Cristina, Jousse-Joulin, Sandrine, Devauchelle-Pensec, Valérie, Cornec, Divi, Jamin, Christophe, Pers, Jacques-Olivier, Bordron, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453492/
https://www.ncbi.nlm.nih.gov/pubmed/36091064
http://dx.doi.org/10.3389/fimmu.2022.975963
_version_ 1784785154379612160
author Morel, Marie
Pochard, Pierre
Echchih, Wiam
Dueymes, Maryvonne
Bagacean, Cristina
Jousse-Joulin, Sandrine
Devauchelle-Pensec, Valérie
Cornec, Divi
Jamin, Christophe
Pers, Jacques-Olivier
Bordron, Anne
author_facet Morel, Marie
Pochard, Pierre
Echchih, Wiam
Dueymes, Maryvonne
Bagacean, Cristina
Jousse-Joulin, Sandrine
Devauchelle-Pensec, Valérie
Cornec, Divi
Jamin, Christophe
Pers, Jacques-Olivier
Bordron, Anne
author_sort Morel, Marie
collection PubMed
description Systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) are two autoimmune diseases characterised by the production of pathogenic autoreactive antibodies. Their aetiology is poorly understood. Nevertheless, they have been shown to involve several factors, such as infections and epigenetic mechanisms. They also likely involve a physiological process known as glycosylation. Both SLE T cell markers and pSS-associated autoantibodies exhibit abnormal glycosylation. Such dysregulation suggests that defective glycosylation may also occur in B cells, thereby modifying their behaviour and reactivity. This study aimed to investigate B cell subset glycosylation in SLE, pSS and healthy donors and to extend the glycan profile to serum proteins and immunoglobulins. We used optimised lectin-based tests to demonstrate specific glycosylation profiles on B cell subsets that were specifically altered in both diseases. Compared to the healthy donor B cells, the SLE B cells exhibited hypofucosylation, whereas only the pSS B cells exhibited hyposialylation. Additionally, the SLE B lymphocytes had more galactose linked to N-acetylglucosamine or N-acetylgalactosamine (Gal-GlcNAc/Gal-GalNAc) residues on their cell surface markers. Interestingly, some similar alterations were observed in serum proteins, including immunoglobulins. These findings indicate that any perturbation of the natural glycosylation process in B cells could result in the development of pathogenic autoantibodies. The B cell glycoprofile can be established as a preferred biomarker for characterising pathologies and adapted therapeutics can be used for patients if there is a correlation between the extent of these alterations and the severity of the autoimmune diseases.
format Online
Article
Text
id pubmed-9453492
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94534922022-09-09 Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy Morel, Marie Pochard, Pierre Echchih, Wiam Dueymes, Maryvonne Bagacean, Cristina Jousse-Joulin, Sandrine Devauchelle-Pensec, Valérie Cornec, Divi Jamin, Christophe Pers, Jacques-Olivier Bordron, Anne Front Immunol Immunology Systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) are two autoimmune diseases characterised by the production of pathogenic autoreactive antibodies. Their aetiology is poorly understood. Nevertheless, they have been shown to involve several factors, such as infections and epigenetic mechanisms. They also likely involve a physiological process known as glycosylation. Both SLE T cell markers and pSS-associated autoantibodies exhibit abnormal glycosylation. Such dysregulation suggests that defective glycosylation may also occur in B cells, thereby modifying their behaviour and reactivity. This study aimed to investigate B cell subset glycosylation in SLE, pSS and healthy donors and to extend the glycan profile to serum proteins and immunoglobulins. We used optimised lectin-based tests to demonstrate specific glycosylation profiles on B cell subsets that were specifically altered in both diseases. Compared to the healthy donor B cells, the SLE B cells exhibited hypofucosylation, whereas only the pSS B cells exhibited hyposialylation. Additionally, the SLE B lymphocytes had more galactose linked to N-acetylglucosamine or N-acetylgalactosamine (Gal-GlcNAc/Gal-GalNAc) residues on their cell surface markers. Interestingly, some similar alterations were observed in serum proteins, including immunoglobulins. These findings indicate that any perturbation of the natural glycosylation process in B cells could result in the development of pathogenic autoantibodies. The B cell glycoprofile can be established as a preferred biomarker for characterising pathologies and adapted therapeutics can be used for patients if there is a correlation between the extent of these alterations and the severity of the autoimmune diseases. Frontiers Media S.A. 2022-08-25 /pmc/articles/PMC9453492/ /pubmed/36091064 http://dx.doi.org/10.3389/fimmu.2022.975963 Text en Copyright © 2022 Morel, Pochard, Echchih, Dueymes, Bagacean, Jousse-Joulin, Devauchelle-Pensec, Cornec, Jamin, Pers and Bordron https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Morel, Marie
Pochard, Pierre
Echchih, Wiam
Dueymes, Maryvonne
Bagacean, Cristina
Jousse-Joulin, Sandrine
Devauchelle-Pensec, Valérie
Cornec, Divi
Jamin, Christophe
Pers, Jacques-Olivier
Bordron, Anne
Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy
title Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy
title_full Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy
title_fullStr Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy
title_full_unstemmed Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy
title_short Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy
title_sort abnormal b cell glycosylation in autoimmunity: a new potential treatment strategy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453492/
https://www.ncbi.nlm.nih.gov/pubmed/36091064
http://dx.doi.org/10.3389/fimmu.2022.975963
work_keys_str_mv AT morelmarie abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy
AT pochardpierre abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy
AT echchihwiam abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy
AT dueymesmaryvonne abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy
AT bagaceancristina abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy
AT joussejoulinsandrine abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy
AT devauchellepensecvalerie abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy
AT cornecdivi abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy
AT jaminchristophe abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy
AT persjacquesolivier abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy
AT bordronanne abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy